Viatris: Number of Employees 2010-2024 | VTRS

Interactive chart of Viatris (VTRS) annual worldwide employee count from 2010 to 2024.
  • Viatris total number of employees in 2023 was 38,000, a 2.7% increase from 2022.
  • Viatris total number of employees in 2022 was 37,000, a 0% decline from 2021.
  • Viatris total number of employees in 2021 was 37,000, a 17.78% decline from 2020.
  • Viatris total number of employees in 2020 was 45,000, a 28.57% increase from 2019.
Viatris Annual Employee Count
2023 38,000
2022 37,000
2021 37,000
2020 45,000
2019 35,000
2018 35,000
2017 35,000
2016 35,000
2015 35,000
2014 30,000
2013 20,000
2012 20,000
2011 18,000
2010 13,000
2009 15,500
Sector Industry Market Cap Revenue
Medical Medical Services $13.858B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $96.890B 12.02
Cencora (COR) United States $46.107B 17.62
DiDi Global (DIDIY) China $23.233B 0.00
ICON (ICLR) Ireland $18.679B 16.64
Revvity (RVTY) United States $15.535B 26.63
Avantor (AVTR) United States $15.498B 23.24
Natera (NTRA) United States $15.385B 0.00
BioMerieux (BMXMF) France $13.601B 0.00
Solventum (SOLV) United States $12.636B 0.00
CochLear (CHEOY) Australia $12.565B 0.00
Medpace Holdings (MEDP) United States $10.202B 28.74
Charles River Laboratories (CRL) United States $9.742B 18.41
Sonic Healthcare (SKHHY) Australia $8.273B 0.00
HealthEquity (HQY) United States $7.792B 42.29
Doximity (DOCS) United States $7.787B 49.34
Bausch + Lomb (BLCO) Canada $6.975B 32.47
Life Times (LTH) United States $4.762B 31.52
PACS (PACS) United States $4.502B 0.00
Sotera Health (SHC) United States $4.367B 23.36
Organon (OGN) United States $4.239B 4.28
Surgery Partners (SGRY) United States $3.778B 41.86
BrightSpring Health Services (BTSG) United States $3.070B 65.30
Ardent Health Partners (ARDT) United States $2.577B 0.00
Alignment Healthcare (ALHC) United States $2.546B 0.00
Concentras Parent (CON) United States $2.480B 0.00
Premier (PINC) United States $2.271B 11.34
GoodRx Holdings (GDRX) United States $2.254B 84.86
GeneDx Holdings (WGS) United States $2.057B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
Teladoc Health (TDOC) United States $1.575B 0.00
AMN Healthcare Services Inc (AMN) United States $1.507B 7.57
Progyny (PGNY) United States $1.425B 25.06
Establishment Labs Holdings (ESTA) $1.338B 0.00
Pediatrix Medical (MD) United States $1.319B 12.91
CareDx (CDNA) United States $1.228B 0.00
Agilon Health (AGL) United States $1.123B 0.00
Embecta (EMBC) United States $0.864B 5.76
InnovAge Holding (INNV) United States $0.822B 0.00
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
SBC Medicals (SBC) United States $0.722B 0.00
Auna S.A (AUNA) Luxembourg $0.488B 0.00
Sonida Senior Living (SNDA) United States $0.483B 0.00
Enhabit (EHAB) United States $0.382B 33.04
DocGo (DCGO) United States $0.355B 13.35
COMPASS Pathways (CMPS) United Kingdom $0.309B 0.00
Sera Prognostics (SERA) United States $0.255B 0.00
ModivCare (MODV) United States $0.232B 7.37
Beauty Health (SKIN) United States $0.211B 0.00
Biodesix (BDSX) United States $0.195B 0.00
LifeMD (LFMD) United States $0.192B 0.00
Ascend Wellness Holdings (AAWH) United States $0.178B 0.00
MultiPlan (MPLN) United States $0.136B 0.00
Nutex Health (NUTX) United States $0.127B 0.00
So-Young (SY) China $0.092B 22.35
Harvard Apparatus Regenerative Technology (HRGN) United States $0.059B 0.00
Singular Genomics Systems (OMIC) United States $0.057B 0.00
OncoCyte (OCX) United States $0.049B 0.00
NeueHealth (NEUE) United States $0.041B 1.63
Co-Diagnostics (CODX) United States $0.039B 0.00
IceCure Medical (ICCM) Israel $0.036B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
Pheton Holdings (PTHL) China $0.027B 0.00
Oncology Institute (TOI) United States $0.021B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.007B 0.00
BioNexus Gene Lab (BGLC) $0.007B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00